BioVie (NASDAQ:BIVI) Upgraded at Wall Street Zen

BioVie (NASDAQ:BIVI) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioVie in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioVie currently has a consensus rating of “Sell”.

BioVie Trading Up 4.7%

BioVie stock opened at $1.80 on Friday. The firm has a market capitalization of $13.57 million, a P/E ratio of -0.73 and a beta of 0.57. The stock has a fifty day moving average price of $1.70 and a 200 day moving average price of $1.47. BioVie has a 52 week low of $1.06 and a 52 week high of $9.09.

BioVie (NASDAQ:BIVI) last released its earnings results on Monday, May 11th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BIVI. XTX Topco Ltd acquired a new stake in BioVie during the fourth quarter worth about $25,000. NewEdge Advisors LLC raised its holdings in shares of BioVie by 283.7% in the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after purchasing an additional 40,000 shares during the period. Jane Street Group LLC acquired a new position in shares of BioVie in the 2nd quarter valued at about $57,000. Two Sigma Investments LP acquired a new position in shares of BioVie in the 3rd quarter valued at about $62,000. Finally, Squarepoint Ops LLC acquired a new position in shares of BioVie in the 3rd quarter valued at about $63,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

About BioVie

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.